A large gap in healthcare is nonadherence to proven effective treatments. One important area for reducing morbidity, mortality and cost for patients with chronic diseases that require frequent home, non-healthcare assisted, administration of treatment is the promotion of adherence to treatment recommendations.
Need to develop and integrate biomarkers of asthma into phenotype/endotype-driven asthma management algorithms
More evidence-based, scientifically proven interventions to ensure that scientific information is translated into clinical and public health practices and programs to reduce the burden of asthma and allergies on individuals, families and society
Integrate real time data acquired from or through mobile health care applications (apps) and devices into asthma and allergy management.
Develop disease modifying treatments for asthma and asthma disease prevention.
Prospective studies on acetaminophen and asthma - randomized/controlled/adequately powered - use in pregnancy and asthma development in utero, use in early childhood
Considering the fact that Blacks bear a disproportionate degree of asthma morbidity and mortality, should treatment recommendations be different for Blacks vs. Caucasians?
Study patient-provider communication of asthma self-management requirements to see where gaps in communication may contribute to suboptimal self-management decisions. Examine patients’ decision-making in the home management of asymptomatic and acute. Compare different approaches to the delivery of asthma self-management education and best practices for supporting the patient as they gain competency in this area.
Systematically examine the contribution of unconventional beliefs and negative attitudes to inadequate clinical outcomes for asthma.
Budesonide/fomoterol controller/reliever therapy ('smart' therapy) in large US studies - adults
Adequately powered randomized vitD trials - as primary prevention, and after asthma diagnosis
Bronchial thermoplasty in oral steroid-dependent (high dose certainly >10 mg/day) asthmatics
ICS/LABA/tiotropium fixed triple-combination inhaler therapy
Are there biomarkers or phenotypic characteristics that will allow us to identify the patients with asthma who will experience a more rapid decline in lung function?